Global Alpha 1 Antitrypsin Deficiency Treatment Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Alpha 1 Antitrypsin Deficiency Treatment Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.

According to our (Global Info Research) latest study, the global Alpha 1 Antitrypsin Deficiency Treatment market size was valued at US$ 2101 million in 2023 and is forecast to a readjusted size of USD 3766 million by 2030 with a CAGR of 8.8% during review period.

Global players of Alpha 1 Antitrypsin Deficiency Treatment include Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols, CSL Behring and Kamada Ltd, etc. Top five players occupy for share about 28%. United States is the largest market, with a share about 37%, followed by European Union and China. In terms of product, Augmentation Therapy is the largest segment, with a share over 44%.

This report is a detailed and comprehensive analysis for global Alpha 1 Antitrypsin Deficiency Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Indication and by End Users. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:

Global Alpha 1 Antitrypsin Deficiency Treatment market size and forecasts, in consumption value ($ Million), 2019-2030

Global Alpha 1 Antitrypsin Deficiency Treatment market size and forecasts by region and country, in consumption value ($ Million), 2019-2030

Global Alpha 1 Antitrypsin Deficiency Treatment market size and forecasts, by Indication and by End Users, in consumption value ($ Million), 2019-2030

Global Alpha 1 Antitrypsin Deficiency Treatment market shares of main players, in revenue ($ Million), 2019-2024

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Alpha 1 Antitrypsin Deficiency Treatment

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Alpha 1 Antitrypsin Deficiency Treatment market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols, CSL Behring, Kamada Ltd, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Alpha 1 Antitrypsin Deficiency Treatment market is split by Indication and by End Users. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Indication and by End Users. This analysis can help you expand your business by targeting qualified niche markets.

Market segmentation

Alpha 1 Antitrypsin Deficiency Treatment market is split by Indication and by End Users. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Indication and by End Users. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Indication
Augmentation Therapy
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Diabetes
Other

Market segment by End Users
COPD
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Diabetes

Market segment by players, this report covers
Pfizer
GlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical Industries
Takeda
Baxter
Grifols
CSL Behring
Kamada Ltd
Chiesi Pharmaceuticals
Kedrion Group
Vertex Pharmaceuticals
ProMetic Life Sciences

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Alpha 1 Antitrypsin Deficiency Treatment product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Alpha 1 Antitrypsin Deficiency Treatment, with revenue, gross margin, and global market share of Alpha 1 Antitrypsin Deficiency Treatment from 2019 to 2024.

Chapter 3, the Alpha 1 Antitrypsin Deficiency Treatment competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Indication and by End Users, with consumption value and growth rate by Indication, by End Users, from 2019 to 2030.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Alpha 1 Antitrypsin Deficiency Treatment market forecast, by regions, by Indication and by End Users, with consumption value, from 2024 to 2030.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Alpha 1 Antitrypsin Deficiency Treatment.

Chapter 13, to describe Alpha 1 Antitrypsin Deficiency Treatment research findings and conclusion.